Navigation Links
Covance to Present at the Morgan Stanley Global Healthcare Conference
Date:9/7/2012

PRINCETON, N.J., Sept. 7, 2012 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today announced that it will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 11, 2012 at 9:10 a.m. (ET).  Investors may access a live webcast of the presentation at www.covance.com.  In order to register and download any necessary software, please log on 10 minutes early.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 11,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release (and in the webcast announced in this press release), which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue, earnings growth, and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
2. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
3. Amgen To Present At The Morgan Stanley Global Healthcare Conference
4. Champions Oncology to Present at Rodman & Renshaw Conference
5. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
6. Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
7. PDL BioPharma to Present at Upcoming Investor Conferences
8. CVS Caremark to Present at Morgan Stanley Global Healthcare Conference
9. GP Strategies to Present at the BMO Capital Markets 12th Annual Back to School Education Conference
10. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
11. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... , Jan. 18, 2017  ViewRay, Inc. (Nasdaq: ... first and only clinical MRI-guided radiation therapy system, announced ... of approximately $26.1 million through a private placement ... Management led the financing and was joined by ... LLC and Kearny Venture Partners, and an additional ...
(Date:1/19/2017)... 18, 2017 The Academy of Managed ... Administration (FDA) for its release today of draft ... decision makers can proactively share clinical and economic ... as emerging therapies awaiting FDA approval. ... that AMCP developed during two multi-stakeholder meetings last ...
Breaking Medicine Technology:
(Date:1/19/2017)... Angeles (PRWEB) , ... January 19, 2017 , ... Next ... Act will be repealed by Congressional political games that circumvent health needs of over ... Stand Rally” capture the human anxieties and needs government public servants were suppose to ...
(Date:1/19/2017)... ... 2017 , ... WhoHaha , a digital media company dedicated to creating ... to produce a three-part video series that uses humor to highlight ways to improve ... of AHA’s Healthy For Good™ movement, which is designed to inspire all Americans to ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. ... Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology ... Dr. Li completed his internship in internal medicine at the Emory University and ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... treatments for patients with sleep apnea and TMJ disorders. These conditions are quite ... health. Dr. Rassouli provides personalized care to reduce the risk of these consequences ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... and financial planning services to communities throughout eastern Georgia, is embarking on a ... disease. , Heart disease kills more Americans every year than anything else, yet ...
Breaking Medicine News(10 mins):